Lilley & Co’s AbbVie ABBV Stock Holding History

Lilley & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	$5.01M	Sell	88,736 -2,585	-3%	-$136K	2.23%	10
2014 Q1	$4.69M	Sell	91,321 -2,905	-3%	-$147K	2.15%	12
2013 Q4	$4.98M	Sell	94,226 -1,348	-1%	-$66.3K	2.32%	9
2013 Q3	$4.28M	Sell	95,574 -2,286	-2%	-$101K	2.24%	10
2013 Q2	$4.05M	Buy	+97,860	New	+$4.28M	2.2%	12

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Lilley & Co's ABBV Position: Q2 2014 in Review

Lilley & Co reduced its AbbVie (ABBV) stake by 2.8% in Q2 2014, selling an estimated $136K and leaving 88,736 shares worth $5.01M. The position accounts for 2.23% of the portfolio, ranked #10.

Lilley & Co first reported a position in ABBV in Q2 2013 and has held it in 5 quarters since. 1,457 funds tracked by Wall St. Rank hold ABBV as of Q2 2014.

Lilley & Co held 88,736 shares of AbbVie worth $5.01M as of Q2 2014.
Lilley & Co sold 2,585 AbbVie shares in Q2 2014, an estimated $136K.
AbbVie made up 2.23% of Lilley & Co's portfolio in Q2 2014, its #10 holding.
Lilley & Co first reported a position in AbbVie in Q2 2013 and has held it in 5 quarters since.
1,457 funds tracked by Wall St. Rank held AbbVie as of Q2 2014.

Based on Lilley & Co's 13F filing for Q2 2014, filed 14 Jul 2014.